Merit Med Sys (MMSI) Stock News

Merit Medical Systems (NASDAQ: MMSI) has announced a significant milestone for its SCOUT® Radar Localization technology, which has now been used to treat 750,000 patients worldwide. The wire-free, non-radioactive localization system helps physicians precisely target and remove abnormal breast tissue with accuracy of +/- 1mm.

The company recently introduced SCOUT MD™, a next-generation system featuring four distinct reflector shapes for improved tumor margin mapping. SCOUT technology has been implemented in over 1,100 facilities across 50 countries, with more than 500 cases performed daily and approximately 10,000 cases monthly. The system has been featured in over 100 clinical publications covering nearly 8,500 patients.

Merit Medical Systems (NASDAQ: MMSI) has received CE Mark approval for its Embosphere® Microspheres for use in genicular artery embolisation (GAE) to treat knee osteoarthritis in the European Union. This expanded indication targets a significant market, as osteoarthritis affects approximately 595 million people globally, with the knee being the most commonly affected joint.

Clinical data demonstrates that over 75% of patients treated with Embosphere for GAE achieved clinical success with significant pain reductions sustained through 24 months. The treatment showed superior results compared to corticosteroid injections, with greater improvements in pain and quality of life at 3 months. Embosphere has been used to treat more than 800,000 patients worldwide and has been studied in over 130 pivotal clinical articles over its 25-year history.

Merit Medical Systems (NASDAQ: MMSI) has announced the enrollment of the first patient in its WRAP North America registry study at Bluff City Vascular in Memphis, TN. The registry will evaluate the real-world safety and effectiveness of the WRAPSODY Cell-Impermeable Endoprosthesis (CIE), a device designed to restore vascular access in hemodialysis patients.

The study aims to enroll up to 250 patients across the US and Canada, following them for three years. This registry complements the ongoing WRAP Global registry, which targets 500 non-North American patients. The WRAPSODY CIE received FDA approval in December 2024 and Health Canada approval in April 2025, following earlier approvals in the EU and Brazil.

Merit Medical Systems (NASDAQ: MMSI) has launched the Prelude Wave™ Hydrophilic Sheath Introducer with SnapFix™ Securement Technology in the US market. This innovative medical device offers significant improvements over competing products, including twice the lubricity, twice the resistance to buckling and kinking, and 40% less insertion force.

The device addresses critical challenges in radial access procedures, where radial artery spasm occurs in up to 20% of patients and arterial occlusion affects approximately 4.6% of cases. The SnapFix technology provides twice the adhesive strength compared to leading competitors, with superior physician ratings for performance and ease of use.

Merit Medical Systems (NASDAQ:MMSI) reported strong Q2 2025 financial results, with revenue reaching $382.5 million, up 13.2% year-over-year. The company demonstrated solid performance with constant currency revenue growth of 12.5% and organic growth of 6.7%. Notable metrics include non-GAAP EPS of $1.01 (up 9.8%) and free cash flow generation of $89.1 million in H1 2025.

The company has raised its full-year 2025 guidance, now expecting revenue between $1.495-$1.507 billion (10-11% growth) and non-GAAP EPS of $3.52-$3.72. Additionally, Merit announced the acquisition of Biolife, a hemostatic devices manufacturer, and appointed Martha Aronson as new President and CEO, effective October 3, 2025.

Merit Medical Systems (NASDAQ: MMSI) has appointed Martha Aronson as its new President and CEO, effective October 3, 2025. Founder Fred Lampropoulos will transition from his current role as President and CEO to continue serving as Chairman of the Board. Aronson brings extensive healthcare experience, having managed global businesses worth $500M-$1B at companies including Ecolab and Hill-Rom.

Additionally, Merit announced preliminary Q2 2025 revenue of $380-384 million, representing a 12-14% increase year-over-year. On a constant currency basis, revenue grew 11-13%. The company will release complete Q2 2025 financial results on July 30, 2025.

Merit Medical Systems (NASDAQ: MMSI), a leading healthcare technology manufacturer, has scheduled its second quarter 2025 financial results announcement for July 30, 2025, after market close. The company will host an investor conference call the same day at 5:00 p.m. Eastern Time.

Founded in 1987, Merit Medical specializes in proprietary medical devices for interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. The company maintains a global presence with over 800 sales and clinical support professionals and approximately 7,300 employees worldwide.

Merit Medical Systems (NASDAQ: MMSI) has acquired Biolife Delaware for approximately $120 million in cash and assumed liabilities. Biolife's StatSeal® and WoundSeal® hemostatic products address a $350M global market opportunity and are expected to add $18 million in revenue annually starting in FY2026. The acquisition is projected to contribute $10-11 million in revenue for the remainder of 2025. While slightly dilutive to 2025 non-GAAP profitability, the deal is expected to be accretive to non-GAAP margins in 2025 and earnings in 2026. Merit has updated its 2025 guidance, now expecting net sales of $1.480-$1.501 billion (9-11% growth) and non-GAAP EPS of $3.28-$3.41.

Merit Medical Systems (NASDAQ: MMSI) has received Health Canada approval for its WRAPSODY Cell-Impermeable Endoprosthesis (CIE), a device designed to treat vascular access stenosis in hemodialysis patients. The device features a unique tri-layer design with superior clinical outcomes demonstrated in the WAVE trial. At 12 months, WRAPSODY showed significantly higher target lesion primary patency (70.1% vs 41.6%) and access circuit primary patency (58.1% vs 34.4%) compared to standard angioplasty. The device, which received FDA approval in December 2024 and CE Mark for European use, will be immediately commercialized throughout Canada from Merit's Toronto distribution center. The innovative design includes an expandable nitinol stent frame, a cell-impermeable middle layer, and a novel inner layer to reduce complications.